PUBLISHER: DelveInsight | PRODUCT CODE: 1462258
PUBLISHER: DelveInsight | PRODUCT CODE: 1462258
"XADAGO Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about XADAGO for Parkinson's disease in the seven major markets. A detailed picture of the XADAGO for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the XADAGO for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XADAGO market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.
XADAGO tablets contain safinamide as the mesylate salt. Safinamide mesylate is (S)-2-[[4-[(3-fluorophenyl) methoxy] phenyl] methyl] aminopropanamide methanesulfonate (1:1). XADAGO is available as 50 mg and 100 mg film-coated tablets for oral administration. Each tablet contains 65.88 mg or 131.76 mg of safinamide mesylate, equivalent to 50 mg or 100 mg, respectively, of the safinamide-free base. The tablets also contain the following inactive ingredients: colloidal silicon dioxide, crospovidone, hypromellose, iron oxide (red), magnesium stearate, microcrystalline cellulose, polyethylene glycol 6000, potassium aluminum silicate, and titanium dioxide.
Dosage and administration
Mechanism of action
The precise mechanism by which XADAGO exerts its effect in Parkinson's disease is unknown. XADAGO is an inhibitor of monoamine oxidase B (MAO-B). Inhibition of MAO-B activity, by blocking the catabolism of dopamine, is thought to result in an increase in dopamine levels and a subsequent increase in dopaminergic activity in the brain.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
XADAGO Analytical Perspective by DelveInsight
This report provides a detailed market assessment of XADAGO for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of XADAGO for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.